SPRAVATO® for Treatment-Resistant Depression in Green Bay: An Honest Guide

spravato for treatment resistant depression near me in green bay wi

Roughly 30 percent of people with major depressive disorder will not achieve adequate relief after trying two or more antidepressants — a patient population for whom the FDA specifically developed a new treatment pathway. SPRAVATO® (esketamine) is not a repackaged antidepressant; it is an FDA-approved nasal spray indicated for treatment-resistant depression that operates through an entirely different mechanism than SSRIs, SNRIs, or TCAs. At AVIVA in Green Bay, Wisconsin, we offer SPRAVATO® treatment within a certified provider network, and we want patients across northeastern Wisconsin to understand exactly what this therapy involves before they make a decision.

What Is SPRAVATO® and How Does It Differ from IV Ketamine?

SPRAVATO® is the brand name for esketamine, an S-enantiomer of ketamine developed and approved by the FDA specifically for two indications: treatment-resistant depression (TRD) in adults, and major depressive disorder (MDD) with acute suicidal ideation or behavior. This distinction from IV ketamine matters clinically. While IV ketamine is used off-label for psychiatric conditions and lacks FDA approval for those indications, SPRAVATO® has undergone the full FDA approval process and carries specific labeling for TRD. It is not the same drug delivered by a different route; it is a distinct formulation with its own clinical trial data, approval pathway, and prescribing requirements.

SPRAVATO® is self-administered as a nasal spray under the direct supervision of a certified healthcare provider. Because of the risk of dissociation, perceptual disturbances, and other acute effects, patients cannot take SPRAVATO® at home. Every session at AVIVA follows the required REMS (Risk Evaluation and Mitigation Strategy) protocol: you administer the nasal spray in our office, we monitor you for at least two hours, and you may not drive yourself home. Julie Podlasik, CRNA, APNP, and our clinical team are certified to supervise SPRAVATO® sessions, and our environment is designed to make those two hours as calm and comfortable as possible.

Treatment Schedule and What to Expect

The FDA-approved treatment schedule for SPRAVATO® begins with an induction phase: two sessions per week for the first four weeks, followed by one session per week during weeks five through eight, and then a maintenance phase of once weekly or once every two weeks depending on clinical response. Some patients respond during the induction phase; others require the full schedule to experience meaningful benefit. As with any treatment, results vary by individual, and we monitor your response carefully throughout and adjust the plan as needed.

Who qualifies for SPRAVATO®? The approved indication requires that adults have not had adequate response to at least two different antidepressants of adequate dose and duration in the current depressive episode. This is a specific threshold, and our team will review your medication history carefully during your intake evaluation. SPRAVATO® is typically used alongside a current oral antidepressant, not as a standalone therapy, which means we will also discuss your existing medication regimen during consultation. If you are exploring your options and want to understand how SPRAVATO® compares to infusion-based approaches, our overview of ketamine infusion therapy provides useful context on how these treatments differ mechanistically.

Insurance Coverage and Cost Considerations

Insurance coverage is one of the most important practical topics for any patient considering SPRAVATO®. Because SPRAVATO® is FDA-approved for TRD and MDD with ASIB, it has a substantially different insurance landscape than IV ketamine, which is used off-label. Many commercial insurance plans, including Medicare, cover SPRAVATO® for qualifying patients, though prior authorization requirements vary by plan. Our team will work with you to understand your coverage before you begin treatment and to navigate the prior authorization process where applicable. We know that cost is a real concern for many families in Green Bay, and we want to help you find the most accessible path forward.

Addressing Common Concerns About SPRAVATO®

One barrier we hear about regularly is uncertainty — patients are not sure whether SPRAVATO® is “really different” from what they have already tried, or they are concerned about the supervised administration format and the time it requires. We address this directly: SPRAVATO® acts on the glutamate system through NMDA receptor modulation, which is a fundamentally different pathway than monoamine-based antidepressants, and the clinical trial evidence supporting it is robust. The supervised format, while requiring time commitment, exists because the acute effects during the session are real and require monitoring. Many patients find that once they experience the sessions, the format feels more manageable than they anticipated.

At AVIVA, we offer both SPRAVATO® and IV ketamine therapy in Green Bay, and we believe in helping patients understand the distinctions between them so they can make informed choices with their treatment team. If you are in Green Bay, Ashwaubenon, Allouez, or elsewhere in Brown County and greater northeastern Wisconsin, we encourage you to reach out for a consultation. Please discuss with your provider which of these options may be right for your specific history.

Frequently Asked Questions

Is SPRAVATO® the same as ketamine?

SPRAVATO® (esketamine) is chemically related to ketamine but is not the same drug. It is the S-enantiomer of ketamine, formulated as a nasal spray, and has received FDA approval specifically for treatment-resistant depression and MDD with acute suicidal ideation or behavior. IV ketamine is used off-label for psychiatric conditions. They have different approval statuses, administration routes, monitoring requirements, and clinical trial data.

Does insurance cover SPRAVATO®?

Because SPRAVATO® is FDA-approved for TRD, many commercial insurance plans and Medicare cover it for qualifying patients, though prior authorization is typically required. Coverage details vary by plan and individual circumstances. Our team will help you verify your benefits and navigate the authorization process before you begin treatment.

What does a SPRAVATO® session feel like?

Most patients experience some degree of dissociation, perceptual changes, dizziness, or sedation during and shortly after administration. These effects are why supervised in-office treatment is required. The experience varies from person to person; some patients describe a dreamlike state while others notice relatively mild effects. Our team prepares you in advance and monitors you throughout the two-hour post-administration period.

How long does SPRAVATO® take to work?

Some patients notice improvement in depressive symptoms within the first two to four weeks of treatment. Others experience gradual change over the full eight-week initial course. Clinical response is individual, and results vary. Ongoing monitoring allows us to evaluate your progress and make appropriate adjustments.

Can I drive after a SPRAVATO® session?

No. SPRAVATO®’s REMS protocol requires that you not drive or operate heavy machinery on the day of each treatment session. You must arrange for a responsible adult to drive you home after every appointment.

Key Takeaways

  • SPRAVATO® is FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation or behavior — a distinct approval status from IV ketamine, which is used off-label.
  • Treatment is administered as a nasal spray in a certified clinical setting with a required two-hour post-dose monitoring period; patients cannot take SPRAVATO® at home.
  • Many insurance plans cover SPRAVATO® for qualifying patients; AVIVA assists with prior authorization and benefits verification.
  • A standard treatment course begins with twice-weekly sessions for four weeks, followed by a gradual tapering to a maintenance schedule.
  • Results vary by individual, and SPRAVATO® is used alongside an oral antidepressant, not as a standalone therapy.

Conclusion

For patients in Green Bay and northeastern Wisconsin who have not found adequate relief from multiple antidepressants, SPRAVATO® offers a medically distinct, FDA-approved option that deserves serious consideration. At AVIVA, we provide SPRAVATO® sessions within a certified, supervised clinical environment led by Julie Podlasik, CRNA, APNP, whose anesthesia background ensures the highest standards of monitoring and care. To learn more about our clinical team and approach, visit our About Us page. If you believe you may qualify for SPRAVATO® treatment, we encourage you to discuss with your provider and contact our team to schedule a consultation — understanding your options is always the right first step.

About Julie Podlasik

Julie Podlasik, CRNA, APNP, is the founder and lead clinician at AVIVA in Green Bay, WI, bringing over 20 years of anesthesia experience to the delivery of IV infusion therapies including ketamine, NAD+, and iron infusions. Her anesthesia background provides a level of medical expertise and safety monitoring that distinguishes AVIVA from typical wellness centers, ensuring precise, closely monitored IV administration for each patient. Alongside functional medicine provider Kayla Guns, FNP, who brings over 14 years of nurse practitioner experience investigating the root causes of deficiencies and metabolic imbalance, Podlasik offers individualized care that considers each patient’s complete health picture.

Medical Disclaimer

The content provided on this page is for educational purposes only and does not constitute medical advice. SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior. Individual results vary, and not every patient will experience the same outcomes. This information does not replace a consultation with a qualified medical provider. Please discuss with your provider whether SPRAVATO® is appropriate for your specific health situation. AVIVA serves patients in Green Bay, WI and surrounding areas.

References

U.S. Food and Drug Administration. SPRAVATO® (esketamine) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s006lbl.pdf

Daly EJ, et al. (2019). Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2019.1189

National Alliance on Mental Illness. Treatment-Resistant Depression. https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/Depression/Treatment-Resistant-Depression

Janssen Pharmaceuticals. SPRAVATO® REMS Program. https://www.spravatorems.com/

Julie Podlasik, CRNA, APNP Ketamine, Botox, IV Vitamins, Fillers

About the Author

I’m Julie Podlasik, CRNA, APNP, and the owner and founder of AVIVA. With over 20 years in anesthesia and ketamine therapy, I’ve built my practice around the belief that people deserve to feel and look their best—inside and out. At AVIVA, I specialize in ketamine therapy, IV vitamins, and aesthetics. Outside of work, I am a wife to Andrew and a mom to two teenage girls. In my spare time, I am a self-proclaimed apple connoisseur and love flowers. I also love to travel the world. I have been to 12 countries and 40 states. My goal is to get to as many as possible. I want my children to view the world through the lens of empathy and someone who knows more than just NE Wisconsin. I also love to spend time hiking or sitting by the pool with my friends and family.

Schedule Your Consultation